Index
995
Tiludronate, 566, 567
Timolol, 477, 478, 676, 958
Tinea, 157
Tinidazole, 172–174
Tinzaparin, 757, 766
Tiotropium, 502, 503, 867, 873
Tipranavir, 137, 139
Tirofiban, 756, 758
Tissue and organ damage, drug induced,
33–39
alterations in glucose metabolism,
36–37
hyperglycaemia, 36–37
hypoglycaemia, 36
auditory damage, 37–38
blood dyscrasia, 31, 35
dermatological reactions, 31, 33–34
rashes and hives, 33–34
stomatitis, 31, 34–35
electrolyte imbalances, 37
hyperkalaemia, 37
hypokalaemia, 37
iatrogenicity, 31, 39
neurological effects, 38
atropine-like (anticholinergic) effects,
38
general central nervous system effects,
38
neuroleptic malignant syndrome, 38
Parkinson-like syndrome, 38
ocular damage, 37
ototoxicity, 37–38
sensory effects, 37–38
superinfections, 31, 35, 81
teratogenicity, 38–39
toxicity, 35–36
liver injury, 36
poisoning, 31, 36
renal injury, 36
TNF (tumour necrosis factor), 235
Tobramycin, 95, 958
Tocilizumab, 265, 266
Tolbutamide, 587
Tolcapone, 382
Tolerance, 25, 27
Tolnaftate, 157, 952
Tolterodine, 824, 825
Tonic-clonic seizure, 352, 355
Topical agents, 949–954
Topical nasal decongestants, 842,
846–849
adverse effects, 846–847
care considerations, 848–849
contraindications and cautions, 846
drug–drug interactions, 847–848
pharmacokinetics, 846
therapeutic actions and indications, 846
Topical nasal steroids, 842, 847, 851–852
adverse effects, 851
care considerations, 851–852
contraindications and cautions, 851
pharmacokinetics, 851
therapeutic actions and indications, 851
Topiramate, 354, 365–368
Topotecan, 222
Toremifene, 212, 215, 609, 614
Toxic effects of drugs, 31–39
adverse effects, 31–33
hypersensitivity, 31, 33
primary actions, 32
secondary actions, 32
drug allergy, 31, 33
interventions, 34
drug-induced tissue and organ damage.
See
Tissue and organ damage,
drug-induced
Toxicity, 35–36
adrenergic agonist, 461–462
iron, 784–785
liver injury, 36
poisoning, 31, 36
renal injury, 36
Toxoids, 273, 279–280
Trachea, 835, 836
Trade name, 2, 7
Tramadol, 402
Trandolapril, 662, 665
Transmitter, 16, 17
Transplant
holistic care, 268–269
rejection, 238
Tranylcypromine, 323
Trastuzumab, 265, 266
Traveller’s diarrhoea, 923, 924–925
Travoprost, 958
Tretinoin, 223, 953
Triamcinolone, 539, 542, 847, 851, 954
Triamterene, 675, 806, 813
Triazolam, 305, 306
Trichinosis, 179, 181
Trichomoniasis, 163, 172
Tricyclic antidepressants (TCA), 316,
317–322
adverse effects, 321
care considerations, 322
contraindications and cautions, 320
drug–drug interactions, 321–322
pharmacokinetics, 320
therapeutic actions and indications,
317–318, 320
Trifluoperazine, 335, 336, 337
Trimipramine, 317, 318, 320
Triptans, 397, 398, 412
adverse effects, 412
contraindications and cautions, 412
drug–drug interactions, 412
pharmacokinetics, 412
therapeutic actions and indications, 412
Triptorelin, 212, 215
Trophozoites, 163, 165, 170–171
Tropicamide, 958
Tropisetron, 932, 934
Troponin, 643, 646
Trypanosomiasis, 163, 172
Tubular reabsorption, 797
Tubular secretion, 797
Tularaemia, 282
Tumour, 229, 232
Tumour necrosis factor (TNF), 235
Typhoid, 106, 107
vaccine, 279
Tyramine, 316, 324
U
Ulcer disease, 897
Unconsciousness, 416, 417
Undecenoic acid, 157
Unstable angina, 713, 715
Upper respiratory tract, 835–836, 843
conditions, 837–838
Upper respiratory tract, drugs acting on,
842–861
adults, 844
antihistamines, 313, 842, 852–856
adverse effects, 855
care considerations, 855–856
contraindications and cautions, 855
drug–drug interactions, 855
pharmacokinetics, 854
therapeutic actions and indications,
854
antitussives, 842, 843–846
adverse effects, 845
care considerations, 845–846
contraindications and cautions, 845
drug–drug interactions, 845
pharmacokinetics, 845
therapeutic actions and indications,
845
children, 844
decongestants.
See
Decongestants
expectorants, 842, 857–859
adverse effects, 858
care considerations, 858–859
contraindications, 858
pharmacokinetics, 857
therapeutic actions and indications,
857
mucolytics, 842, 859–861
adverse effects, 860
care considerations, 860–861
contraindications and cautions, 860
pharmacokinetics, 860
therapeutic actions and indications,
859
older adults, 844
Urea, 950
Ureters, 800
Urethra, 800
Urgency (urinary), 819, 820
Urinary bladder, 800
Urinary frequency, 819, 820
Urinary tract, 800
Urinary tract and bladder, drugs
affecting, 819–831
adults, 820
benign prostatic hyperplasia, drugs for,
828–830
adverse effects, 829
care considerations, 830
contraindications and cautions, 829
drug–drug interactions, 829–830
pharmacokinetics, 829
therapeutic actions and indications,
829
bladder protectant (pentosan
polysulfate sodium), 826–828
adverse effects, 827
care considerations, 827–828
